DEFA14A: ESSA Pharma Seeks Court Approval for Shareholder Cash Distribution Ahead of XenoTherapeutics Acquisition

ESSA Pharma Inc. announced its intent to apply to the Supreme Court of British Columbia for an interim order to hold a special meeting and authorize an initial cash distribution to shareholders prior to the closing of its business combination with XenoTherapeutics, Inc.

Summary

• ESSA Pharma Inc. (ESSA) is proceeding with its previously announced business combination agreement with XenoTherapeutics, Inc. (Xeno), a non-profit biotechnology company, under which Xeno will acquire all issued and outstanding common shares of ESSA.
• ESSA intends to apply to the Supreme Court of British Columbia on August 5, 2025, for an interim order authorizing a special meeting to consider and approve the Transaction, and for an order authorizing an initial cash distribution to its shareholders prior to the closing of the Transaction.
• The total estimated cash distribution to each ESSA shareholder, including the initial distribution and cash payable upon closing, is approximately US$1.91 per Common Share, exclusive of any contingent value rights payments.
• The hearing for these orders is scheduled for August 5, 2025, at 9:45 a.m. (Pacific time) at 800 Smithe Street, Vancouver, British Columbia.
• ESSA intends to file its Petition Record on July 31, 2025, and response materials from affected parties should be received by ESSA's counsel by 1:00 p.m. (Vancouver time) on July 31, 2025.

Sentiment

Score: 7

Explanation: The filing outlines the procedural steps for a previously announced business combination, including an estimated cash distribution to shareholders. This provides clarity on the transaction's progress and a tangible benefit for shareholders, indicating a positive step towards the completion of the deal. However, the company is being acquired, which means it ceases to exist as an independent entity, and there are numerous risks associated with the transaction's completion.

Positives

• Shareholders are estimated to receive approximately US$1.91 per Common Share in cash, plus potential contingent value rights payments, upon completion of the transaction.
• The application for a Distribution Order aims to expedite the distribution of cash to shareholders prior to the transaction closing, providing earlier liquidity.

Negatives

• The company is being acquired, indicating a cessation of its previous operations as a standalone entity focused on prostate cancer therapies.
• The transaction involves significant costs and potential for litigation, which could impact the final outcome or timing.

Risks

• Completion of the Transaction on anticipated terms and timing, including obtaining required securityholder, regulatory, and court approvals, and satisfaction of other conditions.
• Potential litigation relating to the Transaction that could be instituted by or against ESSA, Xeno, XOMA Royalty Corporation, or their respective directors or officers.
• Risk that disruptions from the Transaction will harm ESSA's business, including current plans and operations.
• Ability of ESSA to retain and hire key personnel.
• Potential adverse reactions or changes to business relationships resulting from the announcement or completion of the Transaction.
• Continued availability of capital and financing and rating agency actions.
• Legislative, regulatory, and economic developments affecting ESSA's business.
• Accuracy of ESSA's financial projections.
• General business, market, and economic conditions.
• Certain restrictions during the pendency of the Transaction that may impact ESSA's ability to pursue certain business opportunities or strategic transactions.
• Unpredictability and severity of catastrophic events, including acts of terrorism, pandemics, outbreaks of war or hostilities.
• Significant transaction costs associated with the Transaction.
• Possibility that the Transaction may be more expensive to complete than anticipated due to unexpected factors or events.
• Competitive responses to the Transaction.
• Risks and uncertainties pertaining to ESSA's business as set forth in its Annual Report on Form 10-K dated December 17, 2024, and in the upcoming Proxy Statement.

Future Outlook

The company anticipates the completion of the business combination with XenoTherapeutics, including obtaining necessary approvals and making a cash distribution to shareholders. The transaction is subject to various risks and uncertainties, and the final terms and timing may differ from current expectations.

Industry Context

This announcement reflects a strategic shift for ESSA Pharma, moving from a prostate cancer therapy developer to being acquired by a non-profit biotechnology company. This could indicate a challenging environment for smaller biotech firms or a strategic decision to monetize assets for shareholders. The acquisition by a non-profit suggests a different kind of value proposition than a typical commercial merger.

Legal Proceedings

• The company intends to apply to the Supreme Court of British Columbia for an interim order and a distribution order on August 5, 2025.
• Potential litigation relating to the Transaction could be instituted by or against ESSA, Xeno, XOMA Royalty Corporation, or their respective directors or officers.

Stakeholder Impact

• Shareholders are expected to receive approximately US$1.91 per Common Share in cash, plus potential contingent value rights payments, upon completion of the transaction, and will be asked to approve the transaction at a special meeting.
• The filing notes a risk regarding the ability to retain and hire key personnel, implying potential impact on employees due to the transaction.
• Potential adverse reactions or changes to business relationships resulting from the announcement or completion of the Transaction are noted as a risk.

Next Steps

• ESSA Pharma Inc. will apply to the Supreme Court of British Columbia on August 5, 2025, for an interim order and a distribution order.
• A special meeting will be held to consider and approve the Transaction, pending court authorization.
• ESSA intends to file its Petition Record on July 31, 2025.
• The Proxy Statement and other relevant documents will be filed with the SEC and sent to securityholders.
• The Transaction is expected to close, subject to securityholder, regulatory, and court approvals, and satisfaction of other conditions.

Key Dates

Recommendation

The filing provides an update on the procedural steps for a previously announced acquisition, including an estimated cash payout to shareholders. While the cash distribution is a positive for current shareholders, the company is being acquired, limiting future independent growth potential. The recommendation is 'hold' because the transaction is progressing as expected, and the estimated payout provides a clear value proposition for existing shareholders, but there's no new information that would warrant a 'buy' for new investors given the impending acquisition, nor a 'sell' unless an investor believes the deal will fall through or the payout is less than expected. The risks associated with the transaction's completion are also noted.

Keywords

ESSA Pharma, XenoTherapeutics, business combination, acquisition, cash distribution, prostate cancer, biotechnology, SEC filing, DEFA14A, merger, shareholder payout, court order, British Columbia Supreme Court